清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Rituximab, lenalidomide, and ibrutinib alone and combined with dose adjusted chemotherapy for patients with high risk diffuse large B-cell lymphoma.

作者
Jason R. Westin,Yasuhiro Oki,Luis Fayad,Loretta J. Nastoupil,Francesco Turturro,Frederick B. Hagemeister,Vishwanath Sathyanarayanan,Ken H. Young,Timothy J. McDonnell,Hubert H. Chuang,Shouhao Zhou,Sattva Swarup Neelapu,Richard Eric Davis
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:34 (15_suppl): TPS7575-TPS7575 被引量:2
标识
DOI:10.1200/jco.2016.34.15_suppl.tps7575
摘要

TPS7575 Background: Diffuse large B-cell Lymphoma (DLBCL), the most common lymphoid malignancy, is categorized by the putative cell of origin (COO) classification system into germinal center (GCB) and non-GCB subtypes. Both the immunomodulatory agent lenalidomide (L) and BTK inhibitor ibrutinib (I) have shown activity in the non-GCB DLBCL subtype as single agents and in combination with chemotherapy. Separate randomized phase III trials of RCHOP alone and +L or +I are ongoing in non-GCB DLBCL. Preclinical studies demonstrate L+I results in synthetic lethality in non-GCB DLBCL via interferon signaling (Yang et al, Cancer Cell, 2012), but no trials have evaluated the efficacy in newly diagnosed patients. We present the first “window of opportunity” trial to use targeted therapy (rituximab, R+L+I) alone prior to chemotherapy in newly diagnosed DLBCL. Methods: In this investigator initiated phase II trial, patients receive standard R dosing q 21 days (d), L 25mg po d1-10, I 560mg po d1-21, and after two 21d RLI cycles or earlier if disease progression will start RLI-EPOCH q 21d for 6 cycles, without maintenance therapy. EPOCH will be dose adjusted based on standard criteria, capped at level +2. L+I dosing may be reduced if significant toxicity criteria are met. Key eligibility criteria include histologically confirmed, treatment-naïve non-GCB DLBCL, age ≥ 18, adequate performance status and organ function, and measurable disease. COO will be determined via immunohistochemistry for eligibility, and NanoString (Scott et al, Blood. 2014) for confirmation. Patients will be restaged with PET/CT using Lugano criteria (Cheson et al, JCO 2014). The primary objectives are to determine the overall response rate after two RLI cycles and complete response rate after 6 RLI+EPOCH cycles. Secondary objectives include safety and survival outcomes. Exploratory objectives include evaluation of baseline and therapy induced changes in gene and protein expression, mutations, minimal residual disease monitoring, and immune cell subsets in comparison with clinical outcomes. The trial will accrue 60 patients, and employs Bayesian futility and toxicity monitoring rules. Clinical trial information: NCT02636322.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
光亮的幻桃完成签到,获得积分10
7秒前
16秒前
hy完成签到,获得积分10
18秒前
nano完成签到 ,获得积分10
27秒前
RZH发布了新的文献求助10
36秒前
机智的如曼完成签到,获得积分10
46秒前
Xzx1995完成签到 ,获得积分10
48秒前
FashionBoy的应助被科研通管家采纳,获得10
51秒前
fairytaler的应助被科研通管家采纳,获得10
51秒前
现代的初之完成签到,获得积分10
57秒前
大模型的应助被蜗牛好好飞采纳,获得10
58秒前
ChatGPT完成签到,获得积分10
1分钟前
慕青的应助被蜗牛好好飞采纳,获得10
1分钟前
夏同学完成签到 ,获得积分10
1分钟前
今后的应助被蜗牛好好飞采纳,获得10
1分钟前
wwrjj完成签到,获得积分0
1分钟前
搜集达人的应助被cc采纳,获得10
1分钟前
大模型的应助被蜗牛好好飞采纳,获得10
1分钟前
1分钟前
1分钟前
御坂10576号完成签到,获得积分10
1分钟前
1分钟前
义气的雅琴完成签到,获得积分10
1分钟前
cc发布了新的文献求助10
1分钟前
NexusExplorer的应助被蜗牛好好飞采纳,获得10
1分钟前
Harlotte完成签到 ,获得积分0
1分钟前
蒋不惜完成签到,获得积分10
1分钟前
changfox完成签到,获得积分10
1分钟前
hyk完成签到 ,获得积分10
1分钟前
milalala完成签到 ,获得积分10
1分钟前
浚稚完成签到 ,获得积分10
1分钟前
1分钟前
冷傲的夜白完成签到,获得积分10
1分钟前
岳晓燕完成签到 ,获得积分10
1分钟前
1分钟前
清脆代真发布了新的文献求助50
1分钟前
2分钟前
谭访冬完成签到,获得积分10
2分钟前
MUAN完成签到 ,获得积分10
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8173230
求助须知:如何正确求助?哪些是违规求助? 9565593
关于积分的说明 21780525
捐赠科研通 7767429
什么是DOI,文献DOI怎么找? 3431542
关于科研通互助平台的介绍 2555764
邀请新用户注册赠送积分活动 2476697